SEC Form 13F
| Report period | 2025-09-30 |
|---|---|
| Publicly available | 2025-11-14 |
| Reported value | $16,369,175 |
| Positions | 8 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| Ovid Therapeutics, Inc. | OVID | COM | $9,791,595 | 7,531,996 |
| Equillium, Inc. | EQ | COM | $2,609,717 | 1,824,977 |
| Xilio Therapeutics, Inc. (formerly Akrevia Therapeutics) | XLO | COM | $1,243,084 | 1,475,121 |
| Shattuck Labs, Inc. | STTK | COM | $1,232,329 | 515,619 |
| Lyell Immunopharma, Inc. | Unresolved | COM | $891,365 | 54,887 |
| American Well Corporation | AMWL | COM | $478,061 | 77,733 |
| Rani Therapeutics Holdings, Inc. | RANI | COM | $101,554 | 203,190 |
| Standard Biotools, Inc. | LAB | COM | $21,470 | 16,515 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.